Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Safety And Efficacy Of Tyrosine Kinase Inhibitor Cessation For Chronic Myeloid Leukemia Patients With Stable Molecular Response In A Real World Population

NCT04626024 is registered in ClinicalTrials.gov with Baylor College of Medicine as lead sponsor.

NCT NCT04626024
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04626024 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Safety And Efficacy Of Tyrosine Kinase Inhibitor Cessation For Chronic Myeloid Leukemia Patients With Stable Molecular Response In A Real World Population
Lead sponsor
Baylor College of Medicine
Phase
Phase 2
Overall status
Active, not recruiting
Start date
December 22, 2020
Completion date
November 15, 2028
Enrollment
17 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

chronic myeloid leukemia, chronic myeloid leukemia in remission, chronic myeloid leukemia, bcr/abl-positive, in remission